VOR
HEALTHCAREVor Biopharma Inc
AI Insight
What's Moving VOR Today?
No stock-specific AI insight has been generated for VOR yet. Check back soon — insights are generated from recent news analysis.
52-Week Range
$5.80$65.80
$14.85
Fundamentals
Market Cap$810M
P/E Ratio—
EPS$-70.40
Dividend Yield—
Dividend / Share—
ROE-125.4%
Profit Margin—
Debt / Equity—
Trading
Volume1.3M
Avg Volume (10D)—
Shares Outstanding54.2M
VOR News
21 articles- Telitacicept Receives NMPA Approval for the Treatment of Sjögren’s Disease in ChinaYahoo Finance·Jun 8, 2026
- Telitacicept Receives NMPA Conditional Approval for the Treatment of IgA Nephropathy in ChinaYahoo Finance·Jun 8, 2026
- Why This Fund Made a $66 Million Bet on Damora Therapeutics Amid a 700% SurgeMotley Fool·May 30, 2026
- Dyne Stock Is Up 56%. Here's What a $14 Million Stake Reduction Could MeanMotley Fool·May 30, 2026
- Vor Biopharma (VOR) price target decreased by 10.34% to 37.13MSN·May 30, 2026
- Vor Bio to Participate in the 2026 Jefferies Global Healthcare ConferenceYahoo Finance·May 28, 2026
- We're Hopeful That Vor Biopharma (NASDAQ:VOR) Will Use Its Cash WiselyYahoo Finance·May 15, 2026
- Vor Bio Announces Publication of Interim Analysis of TELIGAN, a China Phase 3 Trial of Telitacicept in IgA Nephropathy, in The New England Journal of MedicineYahoo Finance·May 14, 2026
- Vor Bio Reports First Quarter 2026 Financial Results and Provides Corporate UpdateYahoo Finance·May 13, 2026
- Wall Street Analysts Believe Vor Biopharma (VOR) Could Rally 124.59%: Here's is How to TradeYahoo Finance·May 7, 2026
- Does Vor Biopharma (VOR) Have the Potential to Rally 117% as Wall Street Analysts Expect?Yahoo Finance·Apr 20, 2026
- Vor Biopharma (VOR) Upgraded to Buy: Here's WhyYahoo Finance·Apr 2, 2026
- Wall Street Analysts Predict a 107.82% Upside in Vor Biopharma (VOR): Here's What You Should KnowYahoo Finance·Apr 2, 2026
- Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswire Inc.·Apr 1, 2026
- Vor Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate UpdateYahoo Finance·Mar 30, 2026
- Vor Bio Doses First Patient in Global Phase 3 UPSTREAM SjD Registrational Trial of Telitacicept in Primary Sjögren’s DiseaseYahoo Finance·Mar 30, 2026
- Vor Bio Announces $75 Million Private Placement with TCGXYahoo Finance·Mar 27, 2026
- Vor Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Yahoo Finance·Mar 23, 2026
- Vor Bio to Participate in the 46th Annual TD Cowen Health Care ConferenceYahoo Finance·Feb 23, 2026
- Vor Bio to Participate in the 44th Annual J.P. Morgan Healthcare ConferenceYahoo Finance·Jan 6, 2026
- Vor Bio Appoints RA Capital’s Andrew Levin, M.D., Ph.D., and Forbion’s Wouter Joustra to Board of DirectorsYahoo Finance·Dec 23, 2025
All 21 articles loaded
Price Data
Open$14.76
Previous Close$14.94
Day High$15.25
Day Low$14.65
52 Week High$65.80
52 Week Low$5.80
52-Week Range
$5.80$65.80
$14.85
Fundamentals
Market Cap$810M
P/E Ratio—
EPS$-70.40
Dividend Yield—
Dividend / Share—
ROE-125.4%
Profit Margin—
Debt / Equity—
Trading
Volume1.3M
Avg Volume (10D)—
Shares Outstanding54.2M
About Vor Biopharma Inc
Vor Biopharma, Inc., an early stage cell therapy company, develops hematopoietic stem cell (eHSC) therapies designed for cancer patients. The company is headquartered in Cambridge, Massachusetts.
HEALTHCAREBIOTECHNOLOGY
Company Details
Security TypeCommon Stock
ExchangeNASDAQ
CurrencyUSD
Round Lot—
SICBIOTECHNOLOGY
CIK—
Composite FIGI—
Share Class FIGI—